NMN for Longevity: Dosage, Evidence & Honest Verdict

NMN for Longevity: Dosage, Evidence & Honest Verdict

Overall evidence: Grade C

Every intervention independently graded on human evidence — dose, the rationale, and where the science actually lands.

6 items · grade mix 2A / 1B / 2C / 1D · 15 peer-reviewed citations · last reviewed 2026-07-18

Bottom line

NMN is an NAD+ precursor that, across roughly a dozen short RCTs and multiple 2024 meta-analyses, reliably and dose-dependently raises blood NAD+ — but NAD+ is a biomarker, not a health outcome. The only clinically meaningful positive signal is a single small 2021 RCT (Yoshino, n=25) showing improved muscle insulin sensitivity in prediabetic women, which was never replicated and whose randomization was formally challenged. Pooled RCT data show no significant benefit for glucose or lipid metabolism, and physical-function results are mixed and disproportionately industry-funded. There is zero human evidence that NMN slows aging or extends lifespan — those claims rest entirely on rodent studies — and in the US it sits in regulatory limbo after the FDA excluded it from the dietary-supplement definition in 2022.

A B C D
A — Strong human evidence B — Moderate evidence C — Preliminary / mixed D — Weak / refuted
Educational only — not medical advice. Grades reflect the strength of published human evidence, not a recommendation to take (or avoid) anything — check each item’s verdict tag for direction. Prescription medications and any new supplement should be discussed with your doctor.
A

Raises blood NAD+ levels

Supports
Dose250-900 mg/day, dose-dependentTimingDaily oral; NAD+ rises by day 14-30 and plateaus

What the evidence says: The one consistently reproduced finding: multiple double-blind RCTs and 2024 meta-analyses show NMN raises circulating NAD+ dose-dependently versus placebo. But NAD+ is a surrogate biomarker rather than a clinical outcome, individual response varies enormously, and recent head-to-head work suggests much of the rise may come from gut-microbial conversion to nicotinic acid. The A applies to the biochemical fact only; a higher NAD+ number has not been shown to translate into any hard health benefit.

Key studies: PMID 36482258PMID 35182418PMID 41540253PMID 39116016PMID 38430946
B

Improves skeletal-muscle insulin sensitivity

Mixed
Dose250 mg/day for 10 weeksTimingDaily oral

What the evidence says: Rests on a single small RCT (Yoshino 2021, Science; n=25 prediabetic postmenopausal women) using the gold-standard clamp. It was never replicated, the effect was muscle-specific with no change in body weight, and a published Comment (Brenner) showed the groups were unbalanced at baseline for hepatic fat, questioning the randomization. Pooled meta-analyses of routine glycemic markers do not corroborate a broader metabolic benefit.

Key studies: PMID 33888596PMID 34326206PMID 34326209PMID 39531138
A

Improves general glucose control and blood lipids

Against
Dose250-2,000 mg/day, 14 days-12 weeksTimingDaily oral

What the evidence says: Two independent 2024 meta-analyses (Chen; Zhang) pooling 8-12 RCTs found no significant effect of NMN on fasting glucose, insulin, HbA1c, HOMA-IR or lipids, and Zhang explicitly warned benefits may be exaggerated. Trials were short and mostly in healthy adults, so a benefit in more impaired people is not fully excluded, but the marketed general metabolic-health claim is not supported.

Key studies: PMID 39531138PMID 39116016
C

Improves physical function, aerobic capacity and walking/gait speed

Mixed
Dose250-1,200 mg/day, 6-24 weeksTimingDaily oral; some trials combined with exercise

What the evidence says: Genuinely mixed and sensitive to trial quality/funding. Positive signals — aerobic capacity in runners (Liao, with exercise), 6-minute-walk (Yi), shorter walk time (Morifuji) — are often secondary endpoints and several industry-funded, offset by null trials (Akasaka: no change in grip or walking speed) and a 2025 meta-analysis (Prokopidis) finding no effect on muscle mass, grip or gait speed. Unresolved rather than clearly positive.

Key studies: PMID 34238308PMID 36482258PMID 38789831PMID 36443648PMID 40275690PMID 39185644
C

Lowers blood pressure

Mixed
Dose250-900 mg/dayTimingDaily oral

What the evidence says: A 2026 meta-analysis of 10 RCTs (349 participants) found a small but significant reduction in diastolic BP (~-2.15 mmHg), while systolic was not significantly reduced overall (only in adults 60+). The effect is modest, from a secondary endpoint across heterogeneous trials, and its relevance for actual cardiovascular outcomes is unproven.

Key studies: PMID 41901064
D

Slows aging / extends healthspan or lifespan

Unproven
Dosen/a — no human outcome trials existTimingn/a

What the evidence says: There is zero human evidence for lifespan extension, reduced mortality or lower age-related disease incidence. Every human trial to date lasts 24 weeks or less and measures biomarkers or surrogates (NAD+, or an Aging.Ai calculator in Yi 2022). The lifespan narrative derives entirely from rodent studies and does not currently translate into any demonstrated human anti-aging effect.

Key studies: PMID 36482258

How this works

NMN is a direct biosynthetic precursor of NAD+, a coenzyme central to mitochondrial energy metabolism, DNA repair (PARPs) and sirtuin signaling. NAD+ declines with age, and the longevity hypothesis is that restoring it reverses age-related decline. Recent human head-to-head data suggest oral NMN may raise NAD+ partly via gut-microbial conversion to nicotinic acid rather than by direct uptake. Dosing studied: 250 mg-1,250 mg/day orally (most RCTs 250 mg; dose-ranging to 900-1,200 mg); blood NAD+ rises dose-dependently but with very high inter-individual variability, and no dose is established for any clinical benefit.

Evidence summary

Evidence is deep and concordant on the NAD+ biomarker (multiple RCTs plus meta-analyses) but short, small and mixed on every clinical outcome, with no hard-outcome or lifespan data in humans. Overall Grade C: a reliably NAD+-raising compound whose longevity and functional benefits remain unproven.

Risks & interactions

NMN has been well tolerated with no serious adverse events across RCTs up to 1,250 mg/day for 4-24 weeks, but long-term (>6 month) safety is untested and there is a theoretical concern that boosting NAD+ could support tumor metabolism. Regulatory status is unsettled: in 2022 the US FDA concluded NMN is excluded from the legal definition of a dietary supplement because it was first authorized for investigation as a drug, pushing US-sold NMN into a gray market with no FDA oversight of purity. Buy only third-party-tested material — independent testing has found products under-dosed or degraded.

Who this is for

Reasonable as an experimental, well-tolerated option for metabolically healthy adults specifically interested in restoring age-related NAD+ decline, accepting that clinical benefit is unproven. The only near-clinical signal is in prediabetic/older adults, and even that is unreplicated, so it should not displace proven longevity levers (exercise, sleep, diet). Not appropriate for anyone expecting lifespan extension, and best avoided in pregnancy and in active or prior cancer (theoretical).

Sources

  1. Yoshino M (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. doi:10.1126/science.abe9985 · PMID 33888596
  2. Brenner C (2021). Comment on Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. doi:10.1126/science.abj1696 · PMID 34326206
  3. Klein S (2021). Response to Comment on Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. doi:10.1126/science.abj7375 · PMID 34326209
  4. Liao B (2021). Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. J Int Soc Sports Nutr. doi:10.1186/s12970-021-00442-4 · PMID 34238308
  5. Akasaka H (2022). Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: a prospective, placebo-controlled, double-blind study. Geriatr Gerontol Int. doi:10.1111/ggi.14513 · PMID 36443648
  6. Yi L (2022). The efficacy and safety of beta-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, dose-dependent clinical trial. GeroScience. doi:10.1007/s11357-022-00705-1 · PMID 36482258
  7. Pencina KM (2023). MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of beta-NMN, Increases Circulating NAD and its Metabolome in Middle-Aged and Older Adults. J Gerontol A Biol Sci Med Sci. doi:10.1093/gerona/glac049 · PMID 35182418
  8. Kuerec AH (2024). Towards personalized NMN supplementation: NAD concentration. Mech Ageing Dev. doi:10.1016/j.mad.2024.111917 · PMID 38430946
  9. Morifuji M (2024). Ingestion of beta-NMN increased blood NAD+ levels, maintained walking speed, and improved sleep quality in older adults in a double-blind randomized, placebo-controlled study. GeroScience. doi:10.1007/s11357-024-01204-1 · PMID 38789831
  10. Chen F (2024). Effects of Nicotinamide Mononucleotide on Glucose and Lipid Metabolism in Adults: A Systematic Review and Meta-analysis of RCTs. Curr Diab Rep. doi:10.1007/s11892-024-01557-z · PMID 39531138
  11. Zhang J (2024). Efficacy of oral NMN supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on RCTs. Crit Rev Food Sci Nutr. doi:10.1080/10408398.2024.2387324 · PMID 39116016
  12. Wang JP (2025). Effects of NMN Supplementation on Muscle and Liver Functions Among the Middle-aged and Elderly: A Systematic Review and Meta-analysis of RCTs. Curr Pharm Biotechnol. doi:10.2174/0113892010306242240808094303 · PMID 39185644
  13. Prokopidis K (2025). The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis. J Cachexia Sarcopenia Muscle. doi:10.1002/jcsm.13799 · PMID 40275690
  14. Christen S (2026). The differential impact of three different NAD+ boosters on circulatory NAD+ and microbial metabolism in humans. Nat Metab. doi:10.1038/s42255-025-01421-8 · PMID 41540253
  15. Zhang M (2026). Effects of Nicotinamide Mononucleotide Supplementation on Blood Pressure: A Systematic Review and Meta-Analysis of RCTs. Nutrients. doi:10.3390/nu18060890 · PMID 41901064

Compare the experts: see how this stacks up against every protocol we grade in the Longevity Protocol Comparison →